Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Hale, G, Slavin, S, Goldman, J, Mackinnon, S, Giralt, S, Waldmann, H
פורמט:	Journal article
שפה:	English
יצא לאור:	2002

פריטים דומים

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
מאת: Kottaridis, P, et al.
יצא לאור: (2001)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
מאת: Kottaridis, P, et al.
יצא לאור: (2000)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
מאת: Chakrabarti, S, et al.
יצא לאור: (2004)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
מאת: Watson, C, et al.
יצא לאור: (2004)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
מאת: Clatworthy, MR, et al.
יצא לאור: (2009)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
מאת: Dyer, M, et al.
יצא לאור: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
מאת: Dyer, M, et al.
יצא לאור: (1990)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
מאת: Chakrabarti, S, et al.
יצא לאור: (2002)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
מאת: Watson, C, et al.
יצא לאור: (2005)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
מאת: Maria Kadma da Silva Carriço, et al.
יצא לאור: (2003-06-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
מאת: Lundin, J, et al.
יצא לאור: (2001)

CAMPATH-1H in inflammatory arthritis.
מאת: Watts, R, et al.
יצא לאור: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
מאת: Novitzky, N, et al.
יצא לאור: (2004)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
מאת: Watts, R, et al.
יצא לאור: (1992)

CAMPATH: from concept to clinic.
מאת: Waldmann, H, et al.
יצא לאור: (2005)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
מאת: Willis, F, et al.
יצא לאור: (2001)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
מאת: Lundin, J, et al.
יצא לאור: (2002)

Specificity of monoclonal antibody Campath-1.
מאת: Hale, G, et al.
יצא לאור: (1988)

CAMPATH-1 antibodies in stem-cell transplantation.
מאת: Hale, G, et al.
יצא לאור: (2001)

Campath-1H therapy in refractory ocular inflammatory disease.
מאת: Dick, A, et al.
יצא לאור: (2000)

A personal history of the CAMPATH-1H antibody.
מאת: Waldmann, H
יצא לאור: (2002)

Availability of Campath-1 antibodies for bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1994)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
מאת: Killick, S, et al.
יצא לאור: (1997)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
מאת: Isaacs, J, et al.
יצא לאור: (1996)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
מאת: Lim, S, et al.
יצא לאור: (1993)

In vivo 'purging' of residual disease in CLL with Campath-1H.
מאת: Dyer, M, et al.
יצא לאור: (1997)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
מאת: Williams, R, et al.
יצא לאור: (2000)

The CAMPATH-1 antigen (CDw52).
מאת: Hale, G, et al.
יצא לאור: (1990)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
מאת: Avivi, I, et al.
יצא לאור: (2004)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
מאת: Chakrabarti, S, et al.
יצא לאור: (2002)

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
מאת: Chakraverty, R, et al.
יצא לאור: (2002)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
מאת: Hale, G, et al.
יצא לאור: (1988)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
מאת: Buggins, A, et al.
יצא לאור: (2001)

Nonmyeloablative allogeneic hematopoietic cell transplantation
מאת: Rainer Storb, et al.
יצא לאור: (2016-05-01)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
מאת: Hale, G, et al.
יצא לאור: (1994)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
מאת: Hale, G, et al.
יצא לאור: (1996)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
מאת: Isaacs, J, et al.
יצא לאור: (1995)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
מאת: Naparstek, E, et al.
יצא לאור: (1999)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
מאת: Waldmann, H, et al.
יצא לאור: (1987)